Latest News- Gastroparesis Drugs Market: Prokinetic agents is expected to lead the Drug Class segment during 2025-2029

The Gastroparesis Drugs Market is being driven by Rising global burden of diabetes

The Gastroparesis Drugs Market is expected to grow at a CAGR of 3.5% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 1338.7 million. In the gastrointestinal disorders market, particularly Gastroparesis, vendors are strategically expanding their businesses in emerging economies to tap into the significant revenue potential and broaden their market reach. The rising incidence and prevalence of chronic gastrointestinal disorders, notably in Asia, particularly China and India, present substantial growth opportunities. To capitalize on this trend, companies are expanding their research and development teams and manufacturing facilities in these regions. For instance, Abbott, a key player, is continuously strengthening its R&D presence in emerging markets such as Brazil, India, and China to enhance its product offerings and launch new solutions. This strategic expansion will not only help vendors cater to the untreated population but also fuel market growth. 

Get more information on Gastroparesis Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on segments_for_ai.nslist

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Rising global burden of diabetes
• Increasing prevalence of gastroparesis
• Increasing awareness about gastroparesis

However, the market also witnesses some limitations, which are as follows:

• Stringent regulatory guidelines
• Serious side effects of gastroparesis drugs
• Diagnostic challenges in gastroparesis

Benefits of Buying Global Gastroparesis Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Gastroparesis Drugs Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Gastroparesis Drugs Market encompasses various treatments for Gastroparesis, a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx, with its innovative drug tradipitant, leads the market, joined by metopimazine, deudomperidone, and metoclopramide from ANI Pharmaceuticals and Evoke Pharma. Diabetes, lifestyles, alcohol consumption, and tobacco use trigger Gastroparesis. Symptoms include nausea, vomiting, and digestive disruptions. Potential side effects include liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis. Antiemetics like Erythromcin and Reglan are also used. Clinical trials are ongoing for new treatments.

Market Research Overview

The Gastroparesis Drugs Market is a segment of the larger global pharmaceuticals market, encompassing entities involved in the research and development or production of various drug classes, including gastroprokinetic agents such as Neurogastrx's tradipitant, metopimazine, deudomperidone, and metoclopramide. According to Technavio, the global pharmaceuticals market is projected to grow due to several factors, including the increasing aging population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to be over 60 years old, leading to a significant increase in demand for pharmaceutical products, including those used to treat conditions like gastroparesis.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/